Galaxy Therapeutics Appoints Neurovascular Industry Expert, Dr. Michael Alexander, as Chief Medical Officer
The Californer/10317336

Trending...
MILPITAS, Calif. , June 18, 2025 ~ Galaxy Therapeutics, a leading medical device company specializing in the treatment of brain aneurysms, has announced the appointment of Dr. Michael Alexander as their new Chief Medical Officer. With over two decades of experience in neurosurgery and clinical research, Dr. Alexander brings a wealth of knowledge and expertise to the company.

In his new role, Dr. Alexander will provide global medical leadership for Galaxy's clinical development programs, including the ongoing Saccular Endovascular Aneurysm Lattice (SEAL™) IT IDE trial and future studies focused on treating complex brain aneurysms with the SEAL device. This newly created position highlights Galaxy's commitment to advancing their innovative technology and bringing it to patients worldwide.

Dr. Alexander is a highly distinguished specialist in the field of neurosurgery, with dual training in cerebrovascular surgery and neurointerventional procedures. He has held various leadership positions at prestigious institutions such as Cedars-Sinai Medical Center in Los Angeles, where he currently serves as Professor and Vice Chair of Neurosurgery, Co-Director of the Comprehensive Stroke Center, Director of the Neurovascular Center, and Staff Physician IV (Neurosurgery). He also served as Team Neurosurgeon for the Los Angeles Rams during their 2016-2017 season.

More on The Californer
Prior to joining Cedars-Sinai, Dr. Alexander spent seven years as an Associate Professor at Duke University Medical Center and completed a fellowship at UCLA Medical Center. Despite his new role at Galaxy Therapeutics, he will continue to serve in his current academic and clinical positions.

Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed his excitement about having Dr. Alexander join their executive team. He praised Dr. Alexander's extensive experience in clinical trials and his stellar reputation within the neurointerventional community.

"Dr. Alexander's unmatched clinical trial experience, scientific rigor, and stellar reputation in the neurointerventional community make him an ideal Chief Medical Officer," said Dr. Zaidat. "As such, we are honored to welcome him to the executive team and are confident that he will be instrumental in helping us bring our technology to patients worldwide."

Dr. Zaidat also mentioned that Galaxy Therapeutics will continue to expand its clinical and scientific leadership team as they work towards advancing their innovative SEAL device, designed to address the most challenging aneurysm anatomies.

More on The Californer
Throughout his career, Dr. Alexander has participated in over 45 clinical trials and has been continuously funded by the National Institutes of Health (NIH) for the past 18 years. He is a Past President of the Society of NeuroInterventional Surgery (SNIS), co-author of two textbooks, and has published over 160 peer-reviewed articles in the field of neurovascular disease.

Dr. Alexander received his medical degree from Georgetown University School of Medicine and completed fellowships in Neurovascular and Skull Base Surgery at Barrow Neurological Institute and NeuroIntervention at David Geffen School of Medicine at UCLA.

With Dr. Alexander's expertise and leadership, Galaxy Therapeutics is poised to make significant strides in their mission to provide innovative treatments for brain aneurysms. As they continue to grow, they remain committed to expanding their team with top talent in order to bring their technology to patients around the world.
Filed Under: Business
Show All News | Disclaimer | Report Violation

0 Comments

Latest on The Californer